Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 179 results found since Jan 2013.
Current and future options in cholesterol lowering treatments
Eur J Intern Med. 2023 Feb 20:S0953-6205(23)00050-X. doi: 10.1016/j.ejim.2023.02.010. Online ahead of print.ABSTRACTThe relative risk reduction of cardiovascular events is proportional to the absolute reduction in LDL-C levels, the primary target of therapy, no matter the way of reduction. During the last decades, the therapeutic regimens for reducing the LDL-C levels have been immerged and improved, with favorable effects on the atherosclerotic process and clinical benefits of various cardiovascular outcomes. From a practical view of point, this review is focusing only on the current available lipid lowering agents: stati...
Source: European Journal of Internal Medicine - February 22, 2023 Category: Internal Medicine Authors: Avishay Elis Source Type: research
Self-amplified ROS production from fatty acid oxidation enhanced tumor immunotherapy by atorvastatin/PD-L1 siRNA lipopeptide nanoplexes
Biomaterials. 2022 Nov 3;291:121902. doi: 10.1016/j.biomaterials.2022.121902. Online ahead of print.ABSTRACTDespite the important role of reactive oxygen species (ROS) in battling cancer, ROS production with current approaches has been severely limited by the deficiency of oxy-substrates in tumor microenvironment. Herein, an atorvastatin (Ato)-catalytic self-amplified approach was utilized for sustainable ROS production and enhancing anti-tumor efficacy of PD-L1 silencing. A C18-pArg8-ss-pHis10 lipopeptide based self-assembled nanoplexes was developed to co-encapsulate AMP-activated protein kinase (AMPK) activator of Ato a...
Source: Biomaterials - November 13, 2022 Category: Materials Science Authors: Yan Gao Zilin Song Li Jia Yi Tang Chengcheng Wang Xiuli Zhao Haiyang Hu Dawei Chen Mingxi Qiao Source Type: research
Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic
On December 22, 2021, the United States FDA approved inclisiran, an siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and statin therapy for low-density lipoprotein cholesterol (LDL-C) reduction in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).1 Inclisiran has demonstrated ∼50% time-averaged reduction in LDL-C and offers potential in promoting patient adherence as a twice-yearly long-acting injectable.
Source: Journal of Clinical Lipidology - October 31, 2022 Category: Lipidology Authors: Tommy T. Chiou, Kimberly Tomasi, Pam R. Taub, Michael J. Wilkinson Tags: Brief Communication Source Type: research
Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy
Int J Mol Sci. 2022 Sep 22;23(19):11174. doi: 10.3390/ijms231911174.ABSTRACTIncreased levels of low-density lipoproteins are the main risk factor in the initiation and progression of atherosclerosis. Although statin treatment can effectively lower these levels, there is still a residual risk of cardiovascular events. We hypothesize that a specific panel of stress-sensing molecules (alarmins) could indicate the persistence of silent atherosclerosis residual risk. New Zealand White rabbits were divided into: control group (C), a group that received a high-fat diet for twelve weeks (Au), and a treated hyperlipidemic group wit...
Source: Atherosclerosis - October 14, 2022 Category: Cardiology Authors: Viorel I Suica Elena Uyy Luminita Ivan Raluca M Boteanu Aurel Cerveanu-Hogas Rune Hansen Felicia Antohe Source Type: research
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Curr Atheroscler Rep. 2022 Jul 29. doi: 10.1007/s11883-022-01057-z. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination ...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Nabil G Seidah Damien Gar çon Source Type: research
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
CONCLUSION: Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.PMID:35775133 | DOI:10.1177/10600280221105169
Source: The Annals of Pharmacotherapy - July 1, 2022 Category: Drugs & Pharmacology Authors: Essie Samuel Maya Watford Ugochukwu O Egolum David N Ombengi Hua Ling Drew W Cates Source Type: research
New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention
AbstractPurpose of ReviewThe primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein cholesterol (LDL-C) lowering. Typically, statin therapy remains the first-line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the US Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD ...
Source: Current Cardiovascular Risk Reports - June 25, 2022 Category: Cardiology Source Type: research
Cost-benefit analysis of new lipid-lowering agents
Herz. 2022 Apr 25. doi: 10.1007/s00059-022-05116-8. Online ahead of print.ABSTRACTPatients with atherosclerotic cardiovascular disease have a high risk for subsequent cardiovascular events despite optimal drug treatment including statins and ezetimibe. Dyslipidemia represents a central and direct cause of this, with a frequent failure to achieve the target values recommended in the guidelines. New lipid-lowering substances are increasingly becoming available for treatment of this residual risk. Due to their high cost, cost-effectiveness analyses are required in order to justify their use. Important variables when consideri...
Source: Atherosclerosis - April 25, 2022 Category: Cardiology Authors: Christopher Blaum Natalie Arnold Christoph Waldeyer Source Type: research
